Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President and Representative Director: Michihiro Tsuchiya) announced today that it will transfer its fine chemical operations to two different companies and withdraw from the fine chemical business. Pharmaceutical ingredient manufacturing and sales operations will be transferred to API Corporation (Headquarters: Osaka; President: Taiichi Emura), and food chemical operations will be transferred to TAISHO TECHNOS CO., LTD. (Headquarters: Tokyo; President: Nobuaki Ito).

The transfer of these operations is scheduled for July 1, 2012, and the impact of the transfer on the Company’s operating results is expected to minimal.

API Corporation, which is scheduled to assume responsibility for the Company’s pharmaceutical ingredient operations, is a consolidated subsidiary of Mitsubishi Chemical Corporation, one of the operating companies of the Mitsubishi Chemical Holdings Group. This company is aggressively developing its business, centered on its healthcare and fine chemical operations, in accordance with its corporate philosophy: “API Corporation aims at developing into a ‘creative, R&D-oriented company’ in the field of specialty fine chemicals and contributing to a higher quality of life for people throughout the world.” We anticipate that the addition of Mitsubishi Tanabe Pharma’s pharmaceutical ingredient manufacturing and sales operations will enable API Corporation to achieve impressive levels of growth in the future.

TAISHO TECHNOS, which will handle the Company’s food chemical operations, is a wholly owned consolidated subsidiary of Mitsui Sugar Co., Ltd. With is corporate philosophy of working to “contribute to the realization of a rich and varied food culture and a comfortable living environment,” this company aims to achieve sustainable growth while developing its core businesses of manufacturing and selling food additives as well as preservatives and antifungal agents for industrial use. It is expected that Mitsubishi Tanabe Pharma’s food chemical operations will help TAISHO TECHNOS accelerate its growth and further expand its business.
Mitsubishi Tanabe Pharma, guided by the “Medium-Term Management Plan 11-15—New Value Creation,” is working to build a management foundation for the discovery and global provision of new drugs that respond to unmet medical needs*, and is striving to contribute to improving the quality of life for large numbers of patients around the world. To that end, we have formulated four strategic challenges—(1) Bolstering Our Ability to Discover New Drugs; (2) Advancing Domestic Operations, Centered on New Products, (3) Building a Foundation for the Expansion of Overseas Operations, and (4) Accelerating Operational and Structural Reforms—and we are steadily advancing initiatives aimed at overcoming these challenges.

By reorganizing operations through this business transfer, we aim to further focus management resources on our pharmaceutical operations and to develop into a “Company that Can Continue to Create New Value.”

*Unmet medical needs: Medical needs for which there are no effective treatments or drugs

<Media enquiry>
Corporate Communications Department
TEL : +81-6-6205-5211
API Corporation
Headquarters: 2-4-9, Hiranomachi, Chuo-ku, Osaka, Japan
Tokyo Head Office: Nihonbashi Plaza Building, 9th Floor, 2-3-4, Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan
Representative: Taiichi Emura, President
Capital: ¥4,000 million
Net sales: ¥29,284 million (fiscal year ended March 31, 2011)
Operations: Consigned manufacture of active pharmaceutical ingredients, intermediates and investigational new drugs, consigned research and development, manufacture and marketing of fine chemicals and reagents
Number of Employees: 605 (as of Apr 1, 2012)
Major shareholders: Mitsubishi Chemical Corporation (52.3%)
Mitsubishi Tanabe Pharma Corporation (47.7%)
Operations to be transferred: Pharmaceutical ingredients ¥3.8 billion (Fiscal year ended March 31, 2011)

TAISHO TECHNOS CO., LTD.
Headquarters: Pacific Marks, 7th Floor, Nihonbashi-Tomizawacho Building, 10-18, Nihonbashi-Tomizawacho, Chuo-ku, Tokyo, Japan
Representative: Nobuaki Ito, President
Capital: ¥97.5 million
Net sales: ¥4,410 million (fiscal year ended March 31, 2011)
Operations: Manufacture and sales of food additives (preservatives, shelf-life extender, quality improvement agents, natural colorants, etc.) preservatives and antifungal agents for industrial use, and sanitizers for food product factories
Number of Employees: 90 (as of Apr 1, 2011)
Major shareholders: Mitsui Sugar Co., Ltd. (100%)
Operations to be transferred: Food chemical operations ¥2.5 billion (Fiscal year ended March 31, 2011)